Cargando…

Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy

BACKGROUND: We aimed to investigate the efficacy of locoregional radiotherapy (LRRT) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) receiving chemotherapy combined with anti-programmed cell death receptor-1 monoclonal antibodies (anti-PD-1 mAbs) as first-line treatment and iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Y.-J., Lu, T.-Z., Zhang, H., Fang, M., Chen, B.-J., Guo, Q.-J., Lin, S.-J., Feng, P., Wang, Y., Jiang, T.-C., Gong, X.-C., Pan, J.-J., Li, J.-G., Xia, Y.-F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594020/ https://www.ncbi.nlm.nih.gov/pubmed/37660406 http://dx.doi.org/10.1016/j.esmoop.2023.101629

Ejemplares similares

Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy
por: Li, W.-Z., et al.
Publicado: (2021)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
por: Zeng, Fujuan, et al.
Publicado: (2021)

The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients
por: Yin, Zhenzhen, et al.
Publicado: (2017)

The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy
por: Badaoui, Sarah, et al.
Publicado: (2022)

Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy
por: Yang, Jin-Hao, et al.
Publicado: (2021)

Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy
por: Yan, Wenbin, et al.
Publicado: (2023)

Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis
por: Chen, Ming-Yuan, et al.
Publicado: (2013)

Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
por: Hu, Jiyi, et al.
Publicado: (2020)

Cervical oesophagostomy in patients with severe dysphagia following radiotherapy for nasopharyngeal carcinoma
por: Wang, Y-J, et al.
Publicado: (2014)

Comparison of radiological and clinical features of temporal lobe necrosis in nasopharyngeal carcinoma patients treated with 2D radiotherapy or intensity-modulated radiotherapy
por: Mao, Y-P, et al.
Publicado: (2014)

Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2013)

Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis
por: Yao, Yuyi, et al.
Publicado: (2023)

Locoregional therapy in de novo metastatic breast cancer. The unanswered question
por: Cardoso, Maria-Joao, et al.
Publicado: (2021)

Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy
por: Tian, Y-M, et al.
Publicado: (2014)

Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
por: Yi, Junlin, et al.
Publicado: (2014)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Optimizing induction chemotherapy regimens for radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Li, Ying, et al.
Publicado: (2023)

Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma
por: Jiang, Yanming, et al.
Publicado: (2020)

The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis
por: OuYang, P-Y, et al.
Publicado: (2015)

Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis
por: Du, Chengrun, et al.
Publicado: (2022)

Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy
por: Wee, Chan Woo, et al.
Publicado: (2015)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

M1 stage subdivisions based on (18)F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma
por: Qiu, Hui-Zhi, et al.
Publicado: (2022)

Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017)

Genetic Variations in Radiation and Chemotherapy Drug Action Pathways and Survival in locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy
por: Liu, Huai, et al.
Publicado: (2013)

Survival Benefit of Adding Chemotherapy to Intensity Modulated Radiation in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Ji, Xuemei, et al.
Publicado: (2013)

Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
por: Xu, Amy J., et al.
Publicado: (2019)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
por: Reinhorn, Daniel, et al.
Publicado: (2021)

Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study
por: Jianna, Sun, et al.
Publicado: (2022)

Intensity-modulated radiotherapy combined with sequential cisplatin and fluorouracil chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wu, Mingyao, et al.
Publicado: (2018)

A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy
por: Li, Minying, et al.
Publicado: (2022)

Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
por: Fangzheng, Wang, et al.
Publicado: (2019)

A Nomogram to Predict Survival in Patients With Locoregional Recurrent Nasopharyngeal Carcinoma Receiving Comprehensive Treatment
por: Wei, Ying-Hong, et al.
Publicado: (2022)

CT-Based Radiomics Nomogram for Prediction of Progression-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yan, Chang, et al.
Publicado: (2021)

Evaluation of Acute Locoregional Toxicity in Patients with Breast Cancer Treated with Adjuvant Radiotherapy in Combination with Pazopanib
por: Goyal, Sharad, et al.
Publicado: (2012)

Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Wu, Mingyao, et al.
Publicado: (2020)

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Li, Wen-Fei, et al.
Publicado: (2016)

Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy
por: Li, Wen-Fei, et al.
Publicado: (2015)

Nasopharyngeal Carcinoma Metastatic to the Mandible
por: Huang, Po Hsien, et al.
Publicado: (2010)

Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma
por: Lee, Victor H.F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hkr45rdi6kijsaaghku0f1ui6h